Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart.

Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per ...

Recursion Pharmaceuticals RXRX is gearing up to announce its quarterly earnings on Tuesday, 2025-08-05. Here's a quick overview of what investors should know before the release. Analysts are ...

Before market open on Tuesday, Recursion Pharmaceuticals (RXRX 2.27%) published its latest set of quarterly earnings and business update.

The Motley Fool has a disclosure policy. Why Recursion Pharmaceuticals Stock Tanked on Tuesday Person in a lab gazing into a microscope.© Getty Images ...

Key PointsGAAP revenue surpassed estimates by 24.9% in Q2 2025, driven by milestone payments, including $7 million from Sanofi.